Header Logo

Connection

GEORGE R BLUMENSCHEIN to Breast Neoplasms

Back to Details
This is a "connection" page, showing publications GEORGE R BLUMENSCHEIN has written about Breast Neoplasms.
GEORGE R BLUMENSCHEIN
Connection Strength
1.008
Breast Neoplasms
  1. Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. Cancer Treat Rev. 2013 Jun; 39(4):313-20.
    View in: PubMed
    Score: 0.076
  2. Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer. Cancer. 2013 Jan 01; 119(1):7-15.
    View in: PubMed
    Score: 0.074
  3. Multimodality therapy for locally advanced and limited stage IV breast cancer: the impact of effective non-cross-resistance late-consolidation chemotherapy. Clin Cancer Res. 1997 Dec; 3(12 Pt 2):2633-7.
    View in: PubMed
    Score: 0.027
  4. A phase I open-label dose-escalation study of the anti-HER3 monoclonal antibody LJM716 in patients with advanced squamous cell carcinoma of the esophagus or head and neck and HER2-overexpressing breast or gastric cancer. BMC Cancer. 2017 Sep 12; 17(1):646.
    View in: PubMed
    Score: 0.026
  5. Effects of short-term in vivo administration of G-CSF on bone marrow prior to harvesting. Exp Hematol. 1997 Jan; 25(1):34-8.
    View in: PubMed
    Score: 0.025
  6. A marrow harvest procedure under local anesthesia. Exp Hematol. 1995 Oct; 23(11):1229-32.
    View in: PubMed
    Score: 0.023
  7. cMET and phospho-cMET protein levels in breast cancers and survival outcomes. Clin Cancer Res. 2012 Apr 15; 18(8):2269-77.
    View in: PubMed
    Score: 0.018
  8. High-dose induction chemotherapy of metastatic breast cancer in protected environment: a prospective randomized study. J Clin Oncol. 1987 Feb; 5(2):178-84.
    View in: PubMed
    Score: 0.013
  9. Second neoplasms after adjuvant chemotherapy for operable breast cancer. Am J Clin Oncol. 1986 Jun; 9(3):269-75.
    View in: PubMed
    Score: 0.012
  10. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 1986 May; 46(5):2578-81.
    View in: PubMed
    Score: 0.012
  11. Mitomycin in metastatic breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1985 Nov 15; 56(10):2381-4.
    View in: PubMed
    Score: 0.012
  12. Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer. 2005 Aug 15; 104(4):682-91.
    View in: PubMed
    Score: 0.011
  13. Five-day continuous-infusion vinblastine in the treatment of breast cancer. Cancer. 1985 Jul 15; 56(2):225-9.
    View in: PubMed
    Score: 0.011
  14. A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. Cancer. 1985 Jan 15; 55(2):337-40.
    View in: PubMed
    Score: 0.011
  15. Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. Breast Cancer Res Treat. 1985; 5(3):321-6.
    View in: PubMed
    Score: 0.011
  16. High-dose 1-beta-D-arabinofuranosylcytosine in advanced breast cancer. Oncology. 1985; 42(5):273-4.
    View in: PubMed
    Score: 0.011
  17. Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors. Breast Cancer Res Treat. 1985; 6(3):237-40.
    View in: PubMed
    Score: 0.011
  18. Breast cancer. Cancer Treat Rev. 1984 Dec; 11(4):315-9.
    View in: PubMed
    Score: 0.011
  19. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer. Semin Oncol. 1984 Sep; 11(3 Suppl 1):28-31.
    View in: PubMed
    Score: 0.011
  20. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep. 1984 Jul-Aug; 68(7-8):1039-41.
    View in: PubMed
    Score: 0.011
  21. Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. J Surg Oncol. 1984 Jul; 26(3):205-7.
    View in: PubMed
    Score: 0.011
  22. Radiation-induced breast cancer. Arch Intern Med. 1984 Jun; 144(6):1217-9.
    View in: PubMed
    Score: 0.011
  23. Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat Rep. 1984 May; 68(5):805-6.
    View in: PubMed
    Score: 0.010
  24. Adriamycin, dibromodulcitol, and mitomycin combination chemotherapy for patients with metastatic breast carcinoma previously treated with cyclophosphamide, methotrexate, 5-fluorouracil, vincristine, and prednisone. Cancer. 1984 May 01; 53(9):1841-4.
    View in: PubMed
    Score: 0.010
  25. Tumor-associated fever in breast cancer. Cancer. 1984 Apr 01; 53(7):1596-9.
    View in: PubMed
    Score: 0.010
  26. Significance of drug dose, timing and radiotherapy in adjuvant therapy of breast cancer. Recent Results Cancer Res. 1984; 96:141-7.
    View in: PubMed
    Score: 0.010
  27. FAC + BCG as adjuvant therapy in breast cancer: an 8-year update. Recent Results Cancer Res. 1984; 96:129-32.
    View in: PubMed
    Score: 0.010
  28. The role of progestins in the treatment of breast cancer. Semin Oncol. 1983 Dec; 10(4 Suppl 4):7-10.
    View in: PubMed
    Score: 0.010
  29. Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol. 1983 Dec; 1(12):776-86.
    View in: PubMed
    Score: 0.010
  30. Benign versus malignant hepatic lesions. A diagnostic dilemma with breast cancer patients. Cancer. 1983 Oct 01; 52(7):1308-11.
    View in: PubMed
    Score: 0.010
  31. Cranial nerve palsies in metastatic breast cancer due to osseous metastasis without intracranial involvement. Cancer. 1983 Jul 01; 52(1):180-4.
    View in: PubMed
    Score: 0.010
  32. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. Cancer Treat Rep. 1983 Jun; 67(6):599-600.
    View in: PubMed
    Score: 0.010
  33. Treatment of locoregionally advanced breast cancer with surgery, radiotherapy, and combination chemoimmunotherapy. Int J Radiat Oncol Biol Phys. 1983 May; 9(5):643-50.
    View in: PubMed
    Score: 0.010
  34. Osteoblastic metastatic disease as a therapeutic response to adjuvant chemotherapy in breast cancer. J Surg Oncol. 1983 May; 23(1):32-4.
    View in: PubMed
    Score: 0.010
  35. Serial plasma carcinoembryonic antigen measurements during treatment of metastatic breast cancer. JAMA. 1983 Apr 08; 249(14):1881-6.
    View in: PubMed
    Score: 0.010
  36. Hormonal therapy for metastatic male breast cancer. Arch Intern Med. 1983 Feb; 143(2):237-40.
    View in: PubMed
    Score: 0.010
  37. Effect of diethylaminoethyl-dextran on colony formation of human tumor cells in semisolid suspension cultures. Cancer Res. 1983 Jan; 43(1):210-3.
    View in: PubMed
    Score: 0.010
  38. Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. J Surg Oncol. 1983 Jan; 22(1):45-6.
    View in: PubMed
    Score: 0.010
  39. Treatment of advanced breast cancer with aminoglutethimide after therapy with tamoxifen. Cancer. 1982 Nov 01; 50(9):1708-12.
    View in: PubMed
    Score: 0.009
  40. Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience. Cancer Res. 1982 Aug; 42(8 Suppl):3448s-3450s.
    View in: PubMed
    Score: 0.009
  41. Phase II trial of bruceantin in metastatic breast carcinoma. Am J Clin Oncol. 1982 Aug; 5(4):389-91.
    View in: PubMed
    Score: 0.009
  42. Treatment for meningeal carcinomatosis in breast cancer. Cancer. 1982 Jul 15; 50(2):219-22.
    View in: PubMed
    Score: 0.009
  43. Ploidy, proliferative activity and estrogen receptor content in human breast cancer. Cytometry. 1982 Jul; 3(1):36-41.
    View in: PubMed
    Score: 0.009
  44. Treatment of advanced breast cancer with megestrol acetate after therapy with tamoxifen. Cancer. 1982 Feb 01; 49(3):413-7.
    View in: PubMed
    Score: 0.009
  45. Systemic therapy of metastatic breast cancer: a review of the current trends. Oncology. 1982; 39(3):140-5.
    View in: PubMed
    Score: 0.009
  46. Combination chemotherapy for breast cancer metastatic to bone marrow. Cancer. 1981 Jul 15; 48(2):227-32.
    View in: PubMed
    Score: 0.009
  47. Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer. 1981 Jun 15; 47(12):2798-802.
    View in: PubMed
    Score: 0.009
  48. Tamoxifen-induced hypercalcemia in breast cancer. Cancer. 1981 Jun 15; 47(12):2803-6.
    View in: PubMed
    Score: 0.009
  49. Management of inflammatory carcinoma of breast with combined modality approach - an update. Cancer. 1981 Jun 01; 47(11):2537-42.
    View in: PubMed
    Score: 0.009
  50. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP). Cancer Treat Rep. 1981 Jan-Feb; 65(1-2):33-8.
    View in: PubMed
    Score: 0.008
  51. Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. Cancer. 1980 Aug 01; 46(3):438-45.
    View in: PubMed
    Score: 0.008
  52. Causes of death in breast cancer: a clinicopathologic study. Cancer. 1980 Jul 01; 46(1):162-7.
    View in: PubMed
    Score: 0.008
  53. Human lymphocyte blastogenesis responses to mouse mammary tumor virus. J Natl Cancer Inst. 1980 Mar; 64(3):425-30.
    View in: PubMed
    Score: 0.008
  54. Carcinoembryonic antigen levels in malignant pleural fluids obtained from patients with mammary cancer. Am J Clin Pathol. 1980 Mar; 73(3):386-9.
    View in: PubMed
    Score: 0.008
  55. Alternating noncross-resistant combination chemotherapy and active nonspecific immunotherapy with BCG or MER-BCG for advanced breast carcinoma. Cancer. 1980 Feb 15; 45(4):742-9.
    View in: PubMed
    Score: 0.008
  56. Pulmonary toxicity of mitomycin. Cancer. 1980 Jan 15; 45(2):236-44.
    View in: PubMed
    Score: 0.008
  57. The natural history of breast cancer patients with brain metastases. Cancer. 1979 Nov; 44(5):1913-8.
    View in: PubMed
    Score: 0.008
  58. Tamoxifen. Use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA. 1979 Jul 06; 242(1):49-52.
    View in: PubMed
    Score: 0.008
  59. Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res. 1979 May; 39(5):1552-62.
    View in: PubMed
    Score: 0.007
  60. Hormonal therapy with tamoxifen in male breast cancer. Cancer Treat Rep. 1979 Apr; 63(4):539-41.
    View in: PubMed
    Score: 0.007
  61. Rubidazone in metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):135-6.
    View in: PubMed
    Score: 0.007
  62. Endobronchial metastasis from cancer of the breast. Chest. 1978 Sep; 74(3):319-20.
    View in: PubMed
    Score: 0.007
  63. Endobronchial metastases in breast carcinoma. West J Med. 1978 Sep; 129(3):177-80.
    View in: PubMed
    Score: 0.007
  64. Longitudinal nail banding associated with breast carcinoma unrelated to chemotherapy. Arch Intern Med. 1978 Aug; 138(8):1302-3.
    View in: PubMed
    Score: 0.007
  65. Meningeal carcinomatosis in breast cancer. Cancer. 1978 Jul; 42(1):283-6.
    View in: PubMed
    Score: 0.007
  66. Pituitary-ovarian function in breast cancer patients on adjuvant chemoimmunotherapy. Cancer. 1978 Jun; 41(6):2084-7.
    View in: PubMed
    Score: 0.007
  67. Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer. Cancer Treat Rep. 1978 Mar; 62(3):405-8.
    View in: PubMed
    Score: 0.007
  68. Therapy of advanced breast cancer. N Engl J Med. 1977 Dec 08; 297(23):1291-2.
    View in: PubMed
    Score: 0.007
  69. Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. Cancer. 1987 Oct 15; 60(8):1724-8.
    View in: PubMed
    Score: 0.003
  70. Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. Cancer. 1987 Jun 15; 59(12):1992-9.
    View in: PubMed
    Score: 0.003
  71. Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: a prospective randomized study. J Clin Oncol. 1987 Mar; 5(3):354-64.
    View in: PubMed
    Score: 0.003
  72. Prediction of survival by degree of reactivity to BCG in patients with metastatic breast cancer. Dev Biol Stand. 1986; 58 ( Pt A):357-63.
    View in: PubMed
    Score: 0.003
  73. Phase II study of AMSA and doxorubicin to treat metastatic breast cancer. Oncology. 1986; 43(4):205-7.
    View in: PubMed
    Score: 0.003
  74. A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. Cancer Chemother Pharmacol. 1986; 18(2):157-61.
    View in: PubMed
    Score: 0.003
  75. Trioxifene mesylate in the treatment of advanced breast cancer. Cancer. 1986 Jan 01; 57(1):40-3.
    View in: PubMed
    Score: 0.003
  76. Clonogenic in vitro growth and histologic grading of primary human breast tumors. Int J Cell Cloning. 1985 May; 3(3):143-8.
    View in: PubMed
    Score: 0.003
  77. Management of inflammatory carcinoma of the breast. A combined modality approach. Am J Clin Oncol. 1985 Apr; 8(2):134-41.
    View in: PubMed
    Score: 0.003
  78. Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. Cancer. 1985 Jan 15; 55(2):341-6.
    View in: PubMed
    Score: 0.003
  79. Induction chemotherapy of breast cancer. Prog Clin Biol Res. 1985; 201:105-16.
    View in: PubMed
    Score: 0.003
  80. The management of locally advanced breast cancer: a combined modality approach. Eur J Cancer Clin Oncol. 1984 Nov; 20(11):1353-61.
    View in: PubMed
    Score: 0.003
  81. Phase II study of spirogermanium in the treatment of metastatic breast cancer. Cancer Treat Rep. 1984 Sep; 68(9):1197-8.
    View in: PubMed
    Score: 0.003
  82. Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. Cancer. 1984 May 01; 53(9):1836-40.
    View in: PubMed
    Score: 0.003
  83. Normalization of in vitro sensitivity testing of human tumor clonogenic cells. Cancer Res. 1984 Mar; 44(3):923-8.
    View in: PubMed
    Score: 0.003
  84. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer. 1984 Feb 01; 53(3):384-9.
    View in: PubMed
    Score: 0.003
  85. Combined modality approach in breast cancer with isolated or multiple metastases. Am J Clin Oncol. 1984 Feb; 7(1):45-50.
    View in: PubMed
    Score: 0.003
  86. Carminomycin. A new anthracycline analog in the treatment of advanced breast cancer. Cancer. 1984 Jan 01; 53(1):9-12.
    View in: PubMed
    Score: 0.003
  87. The true predictive value of the human tumor stem cell assay: does a workable assay select for treatment responders? J Clin Oncol. 1984 Jan; 2(1):42-5.
    View in: PubMed
    Score: 0.003
  88. Combination chemotherapy with cyclophosphamide, mitoxantrone and 5-fluorouracil in patients with metastatic breast cancer. Cancer Treat Rev. 1983 Dec; 10 Suppl B:53-5.
    View in: PubMed
    Score: 0.003
  89. Phase II evaluation of vinblastine, methotrexate, and calcium leukovorin rescue in patients with refractory metastatic breast cancer. Cancer. 1983 Mar 01; 51(5):769-72.
    View in: PubMed
    Score: 0.002
  90. Multimodal treatment of locoregionally advanced breast cancer. Cancer. 1983 Mar 01; 51(5):763-8.
    View in: PubMed
    Score: 0.002
  91. Bisantrene, an active new drug in the treatment of metastatic breast cancer. Cancer Res. 1983 Mar; 43(3):1402-4.
    View in: PubMed
    Score: 0.002
  92. A phase I-II study of continuous 5-day infusion mitomycin-C. Am J Clin Oncol. 1983 Feb; 6(1):109-12.
    View in: PubMed
    Score: 0.002
  93. Phase II clinical evaluation of AZQ in metastatic breast cancer. Am J Clin Oncol. 1983 Feb; 6(1):31-3.
    View in: PubMed
    Score: 0.002
  94. Combination chemotherapy with continuous infusion vinblastine and peptichemio for patients with advanced metastatic breast cancer. Am J Clin Oncol. 1982 Oct; 5(5):511-4.
    View in: PubMed
    Score: 0.002
  95. Estrogen receptor status in inflammatory breast carcinoma. J Surg Oncol. 1982 Sep; 21(1):42-4.
    View in: PubMed
    Score: 0.002
  96. AMSA and peptichemio in the treatment of advances metastatic breast cancer: a phase II study. Am J Clin Oncol. 1982 Aug; 5(4):383-7.
    View in: PubMed
    Score: 0.002
  97. Phase II trail of PCNU in refractory advanced breast cancer. Am J Clin Oncol. 1982 Jun; 5(3):249-51.
    View in: PubMed
    Score: 0.002
  98. Peptichemio versus melphalan (L-PAM) in advanced breast cancer. Cancer. 1982 May 01; 49(9):1767-70.
    View in: PubMed
    Score: 0.002
  99. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer. 1982 May 01; 49(9):1762-6.
    View in: PubMed
    Score: 0.002
  100. Effect of timing of initiation of adjuvant chemotherapy on disease-free survival in breast cancer. Breast Cancer Res Treat. 1982; 2(2):163-9.
    View in: PubMed
    Score: 0.002
  101. Dihydroxyanthracenedione: a promising new drug in the treatment of metastatic breast cancer. Ann Intern Med. 1981 Dec; 95(6):694-7.
    View in: PubMed
    Score: 0.002
  102. Vindesine in the treatment of refractory breast cancer: improvement in therapeutic index with continuous 5-day infusion. Cancer Treat Rep. 1981 Sep-Oct; 65(9-10):775-9.
    View in: PubMed
    Score: 0.002
  103. Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer. Cancer Treat Rep. 1981 May-Jun; 65(5-6):465-7.
    View in: PubMed
    Score: 0.002
  104. Prognostic value of prechemotherapy skin tests in patients with metastatic breast carcinoma. Cancer. 1981 Mar 15; 47(6):1369-76.
    View in: PubMed
    Score: 0.002
  105. Combination chemoimmunotherapy with FAC-BCG for metastatic breast cancer: the impact of CMF maintenance chemotherapy. J Surg Oncol. 1981; 18(2):163-72.
    View in: PubMed
    Score: 0.002
  106. CSF carcinoembryonic antigen in meningeal carcinomatosis from breast cancer. JAMA. 1980 Oct 03; 244(14):1601-3.
    View in: PubMed
    Score: 0.002
  107. Leukocyte interferon-induced tumor regression in human metastatic breast cancer, multiple myeloma, and malignant lymphoma. Ann Intern Med. 1980 Sep; 93(3):399-406.
    View in: PubMed
    Score: 0.002
  108. Autologous and homologous immunofluorescent antibody to established breast cancer cell lines. In Vitro. 1980 Jul; 16(7):629-33.
    View in: PubMed
    Score: 0.002
  109. A phase II study of peptichemio in advanced breast cancer. Cancer. 1980 May 15; 45(10):2524-8.
    View in: PubMed
    Score: 0.002
  110. Chemotherapy for advanced male breast cancer. JAMA. 1980 May 02; 243(17):1739-41.
    View in: PubMed
    Score: 0.002
  111. Immune-complex glomerulonephritis secondary to nonspecific immunotherapy. Cancer. 1980 Feb; 45(3):495-7.
    View in: PubMed
    Score: 0.002
  112. Vinblastine given as a continuous 5-day infusion in the treatment of refractory advanced breast cancer. Cancer Treat Rep. 1980 Feb-Mar; 64(2-3):279-83.
    View in: PubMed
    Score: 0.002
  113. Chemoimmunotherapy for metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, methotrexate, L-asparaginase, Corynebacterium parvum, and Pseudomonas vaccine. Cancer Treat Rep. 1980 Jan; 64(1):157-9.
    View in: PubMed
    Score: 0.002
  114. Strategy for evaluation of a new antitumor agent in the treatment of breast cancer. Recent Results Cancer Res. 1980; 70:153-7.
    View in: PubMed
    Score: 0.002
  115. Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. J Surg Oncol. 1979 Dec; 12(4):333-41.
    View in: PubMed
    Score: 0.002
  116. Complete remissions in metastatic breast cancer treated with combination drug therapy. Ann Intern Med. 1979 Dec; 91(6):847-52.
    View in: PubMed
    Score: 0.002
  117. Phase II study of hexamethylmelamine alone and in combination with mitomycin C and vincristine in advanced breast carcinoma. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2053-6.
    View in: PubMed
    Score: 0.002
  118. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Nov; 44(5):1955-62.
    View in: PubMed
    Score: 0.002
  119. Phase II study of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in metastatic breast cancer. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):1961-4.
    View in: PubMed
    Score: 0.002
  120. Postoperative adjuvant chemotherapy with fluorouracil, doxorubicin, cyclophosphamide, and BCG vaccine. A follow-up report. JAMA. 1979 Oct 05; 242(14):1509-13.
    View in: PubMed
    Score: 0.002
  121. Diabetes insipidus and breast cancer. Arch Intern Med. 1979 Sep; 139(9):1009-11.
    View in: PubMed
    Score: 0.002
  122. Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. Cancer. 1979 Aug; 44(2):398-405.
    View in: PubMed
    Score: 0.002
  123. Male breast cancer: a natural history study. Cancer. 1979 Aug; 44(2):748-54.
    View in: PubMed
    Score: 0.002
  124. Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. Cancer. 1979 Jul; 44(1):32-4.
    View in: PubMed
    Score: 0.002
  125. High-dose methotrexate for advanced breast cancer. Cancer Treat Rep. 1979 May; 63(5):757-61.
    View in: PubMed
    Score: 0.002
  126. Phase II study of anguidine in advanced breast cancer. Cancer Treat Rep. 1979 May; 63(5):789-91.
    View in: PubMed
    Score: 0.002
  127. Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. Cancer. 1979 Apr; 43(4):1225-33.
    View in: PubMed
    Score: 0.002
  128. Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. Cancer. 1979 Mar; 43(3):1112-22.
    View in: PubMed
    Score: 0.002
  129. Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. J Surg Oncol. 1979; 11(4):325-32.
    View in: PubMed
    Score: 0.002
  130. Ifosfamide versus cyclophosphamide in combination drug therapy for metastatic breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):115-20.
    View in: PubMed
    Score: 0.002
  131. Phase II study with sequential L-asparaginase and methotrexate in advanced refractory breast cancer. Cancer Treat Rep. 1979 Jan; 63(1):77-83.
    View in: PubMed
    Score: 0.002
  132. Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). J Surg Oncol. 1979; 12(1):27-40.
    View in: PubMed
    Score: 0.002
  133. Thyroid-stimulating hormone and prolactin levels in breast cancer. Arch Intern Med. 1978 Nov; 138(11):1638-41.
    View in: PubMed
    Score: 0.002
  134. Spontaneous regression of breast carcinoma. Arch Intern Med. 1978 Nov; 138(11):1734-5.
    View in: PubMed
    Score: 0.002
  135. Response of disseminated breast cancer to combined modality treatment with chemotherapy and levamisole with or without Bacillus Calmette-Gu?rin. Cancer Treat Rep. 1978 Nov; 62(11):1685-92.
    View in: PubMed
    Score: 0.002
  136. Amphotericin B and combination chemotherapy in the treatment of refractory metastatic breast carcinoma and sarcoma. Cancer Treat Rep. 1978 Oct; 62(10):1565-7.
    View in: PubMed
    Score: 0.002
  137. Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat Rep. 1978 Jul; 62(7):1005-8.
    View in: PubMed
    Score: 0.002
  138. Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. Cancer. 1978 Apr; 41(4):1235-9.
    View in: PubMed
    Score: 0.002
  139. Etiologic factors of hypercalcemia in breast cancer. Tex Med. 1978 Mar; 74(3):52-5.
    View in: PubMed
    Score: 0.002
  140. Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer. 1978 Mar; 41(3):1064-75.
    View in: PubMed
    Score: 0.002
  141. Mitomycin-C and megestrol acetate in treatment of breast cancer refractory to hormonal and combination chemotherapy. Cancer. 1978 Feb; 41(2):392-5.
    View in: PubMed
    Score: 0.002
  142. Adjuvant therapy of stage II, III breast cancer. Recent Results Cancer Res. 1978; 68:123-8.
    View in: PubMed
    Score: 0.002
  143. Chemo immunotherapy of advanced breast cancer with BCG. Recent Results Cancer Res. 1977; (62):143-50.
    View in: PubMed
    Score: 0.002
  144. Chemoimmunotherapy of advanced breast cancer: prolongation of remission and survival with BCG. Br Med J. 1976 Nov 20; 2(6046):1222-5.
    View in: PubMed
    Score: 0.002
  145. Effect of cyclophosphamide on the mitomycin-induced syndrome of thrombotic thrombocytopenic purpura. Cancer Treat Rep. 1985 May; 69(5):565-6.
    View in: PubMed
    Score: 0.001
  146. Potential cardiotoxicity with mitoxantrone. Cancer Treat Rep. 1982 Aug; 66(8):1641-3.
    View in: PubMed
    Score: 0.001
  147. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med. 1982 Feb; 96(2):133-9.
    View in: PubMed
    Score: 0.001
  148. Electrocardiographic changes after adriamycin chemotherapy. Cancer. 1979 Feb; 43(2):465-71.
    View in: PubMed
    Score: 0.000
  149. A pharmacokinetically based phase I-II study of single-dose actinomycin D (NSC-3053). Cancer Treat Rep. 1976 Mar; 60(3):289-91.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.